Physician profile
Rupesh K Dave
NPI 1255525663
$4,687.42
in general payments reported to CMS, 2019-2025
44 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $505 · 2021: $634 · 2022: $733 · 2023: $951 · 2024: $996 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $790.23 | 2019-2024 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $698.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $428.26 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $235.58 | 2020-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $221.77 | 2023-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $185.57 | 2021-2024 | Fasenra, Tezspire, Breztri |
| Inspire Medical Systems, INC. | $156.35 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $155.16 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $153.50 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.35 | 2021-2023 | Glassia |
| Amgen INC. | $128.03 | 2021-2024 | Tezspire |
| Baxter Healthcare | $113.30 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| La Jolla Pharmaceutical Company | $109.90 | 2023-2025 | Giapreza |
| Insmed, INC. | $109.06 | 2019-2025 | Arikayce, Brinsupri |
| Abiomed | $97.32 | 2024 | Impella |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $96.05 | 2023-2024 | Xembify, Prolastin-C Liquid |
| Harmony Biosciences LLC | $75.38 | 2021-2025 | |
| Pfizer INC. | $65.07 | 2020-2021 | |
| Pulmonx Corporation | $64.92 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $59.85 | 2021-2022 | |
| Resmed Corp | $59.27 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $46.75 | 2019 | |
| Abbvie INC. | $44.02 | 2023 | Avycaz |
| Verona Pharma, INC. | $33.75 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $33.30 | 2022 | |
| Philips North America LLC | $31.43 | 2019-2022 | |
| Advanced Respiratory, INC | $30.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $30.09 | 2020-2022 | |
| Ucb, INC. | $23.59 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $23.28 | 2025 | Orencia |
| Janssen Biotech, INC. | $22.89 | 2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $22.74 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $22.52 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $20.99 | 2025 | |
| Vifor Pharma, INC. | $20.95 | 2024 | Zemaira |
| Tandem Diabetes Care, INC. | $20.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ani Pharmaceuticals, INC. | $18.89 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $18.61 | 2025 | Sunosi |
| Alexion Pharmaceuticals, INC. | $15.88 | 2025 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $15.55 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.30 | 2025 | Amvuttra |
| Shire North American Group INC | $14.10 | 2019 | |
| Phadia US INC. | $13.74 | 2019 | |
| Itamar Medical INC | $10.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupesh Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.